Relaxation and aging behaviors in three supercooled liquids: m-toluidine, glycerol, and sucrose benzoate have been studied by shear stress relaxation experiments in the time domain above and below their nominal glass transition temperatures. For the equilibrium state, the current study provides new data on the behavior of organic complex fluids. The shape of the relaxation function as characterized by the stretching exponent beta is discussed considering that a time-temperature master curve can be constructed even though the beta's for the individual response curves at each temperature vary systematically. In the nonequilibrium state, isothermal physical aging experiments at different glassy structures reveal that the effect of the aging process on the mechanical shear relaxation in these simple glass formers is similar to that observed in polymeric and other systems. Departure from the Vogel-Fulcher-Tamman behavior after the samples have aged back to equilibrium in the glassy state is observed for m-toluidine and, less strongly, for glycerol but not for sucrose benzoate. An inherent structure-based energy landscape concept is briefly discussed to account for the slow dynamics during the physical aging process.

Background: Our previous study showed Musashi2 (MSI2) promoted chemotherapy resistance and pernicious biology of pancreatic cancer (PC) by down-regulating Numb and p53. We further explored the novel molecular mechanism involving its oncogenic role in PC development. Methods: We investigated the potential role and mechanism of MSI2 in EGF-induced EMT in PC in vitro and vivo. Results: EGF enhanced EGFR (epidermal growth factor receptor) phosphorylation, induced EMT and activated ZEB1-ERK/MAPK signaling in 2 PC cells. However, MSI2 silencing reversed EGF stimulated function, including inhibiting EGF-promoted EMT-like cell morphology and EGF-enhanced cell invasion and migration. Meanwhile, MSI2 silencing inhibited EGF-enhanced EGFR phosphorylation at tyrosine 1068 and reversed EGF-induced change of the key proteins in EMT and ZEB1-ERK/MAPK signaling (ZEB1, E-cad, ZO-1, β-catenin, pERK and c-Myc). Additionally, MSI2 was co-stained and co-immunoprecipitated with ZEB1, pERK and c-Myc in PC cells by IF and co-IP, implying a close interaction between them. In vivo, MSI2 silencing inhibited pancreatic tumor size in situ and distant liver metastases. A close relationship of MSI2 with EMT and ZEB1-ERK/MAPK signaling were also observed in vivo and human PC samples, which coordinately promoted the poor prognosis of PC patients. Conclusions: MSI2 promotes EGF-induced EMT in PC via ZEB1-ERK/MAPK signaling.

Context Cardiovascular benefits of empagliflozin in patients with type 2 diabetes mellitus (T2DM) have been reported; however, the underlying mechanism remains unknown. Objective We hypothesized that the cardiovascular benefits of empagliflozin are associated with altered gut microbiota and plasma metabolites, and that empagliflozin may be used as an initial treatment for patients with T2DM at risk of cardiovascular diseases (CVDs). Design Randomized, open-label, two-arm clinical trial for 3 months. Setting Hospital. Patients Seventy-six treatment-naïve patients with T2DM and risk factors for CVD. Intervention Treatment with empagliflozin (10 mg/d, n = 40) or metformin (1,700 mg/d, n = 36). Main Outcome Measures We investigated changes in clinical parameters related to glucose metabolism and CVD risk factors, gut microbiota using 16S rRNA gene sequencing, and plasma metabolites using LC-MS. Results We found significant and similar reduction in HbA1c levels and alleviation of glucose metabolism in both groups. However, only empagliflozin improved CVD risk factors. Empagliflozin significantly reshaped the gut microbiota after 1 month of treatment; this alteration was maintained until the end of the trial. Empagliflozin increased the levels of plasma metabolites such as sphingomyelin, but reduced glycochenodeoxycholate, cis-aconitate, and uric acid levels. Concurrently, empagliflozin elevated levels of short-chain fatty acid-producing bacteria such as species from Roseburia, Eubacterium, and Faecalibacterium, and reduced those of several harmful bacteria including Escherichia-Shigella, Bilophila, and Hungatella. Conclusions Empagliflozin may be a superior initial therapy for patients with T2DM at risk of CVDs; its cardiovascular benefits may be associated with shifts in gut microbiota and plasma metabolites.